Covid Vaccine Race

Experts in the management of SARS-CoV-2 educate on CDC and FDA recommendations for approaching administration of booster vaccines, including those for special patient populations.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Jacinda Abdul-Mutakabbir, PharmD; and Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; review what encompasses a bivalent vaccine and give their perspective on how to communicate the role of the vaccine in optimizing protection for patients.

Safety profile in this study showed the frequency of adverse reactions with these boosters were similar or lower than that of either a second or third dose of the original vaccine.

Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc, leads a discussion on the constant evolution of SARS-CoV-2 variants and the impact on vaccine and booster shot development and administration.

Jacinda Abdul-Mutakabbir, PharmD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; and Madeline King, PharmD, BCIDP, examine the efficacy and real-world implications of the COVID-19 booster shot in terms of vaccination protection rates.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP, leads a discussion on the challenges subvariants of SARS-CoV-2 present in terms of vaccination and approaching optimal communication to the public surrounding vaccination.

Expert health professionals share their thoughts on variants of concern vs variants of interest of the SARS-CoV-2 strains as they relate to clinical practice.

In communities of color, hesitancy, mistrust, and access issues all drove low COVID-19 vaccination rates during the pandemic.

Vaxxinity is moving forward with research to bring its UB-612 COVID-19 vaccine to market as a mix-and-match booster to authorized vaccines.

“In the long run, what we will have is a virus that will become endemic in our population," said Donald J. Alcendor, MD. "The idea of thinking we can chase variants with boosters is a failed effort. We must realize that.”

The simple truth is that the long-lasting symptoms of COVID are something we should all be worried about.

Jacinda Abdul-Mutakabbir, PharmD, discusses the difference between the original SARS-CoV-2 strain and subvariant strains.

What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.

The Novavax booster dose administered in a small study induced more robust antibody responses and its safety profile was considered favorable.

Moderna’s new bivalent COVID-19 booster, which includes 25 micrograms each of messenger RNAs from the Wuhan-Hu-1 and Omicron B.1.1.529 variants of SARS-CoV-2, elicited antibody responses that were superior to those elicited by the original vaccine.

Preliminary results from a phase 2/3 trial suggest Pfizer-BioNTech’s Omicron BA.4/BA.5 bivalent COVID-19 booster vaccine provides better protection for younger and older adults.

The Moderna vaccine can be administered to children as young as six years old and the Pfizer-BioNTech vaccine for kids as young as five years old.

A comprehensive cohort study of COVID-19 data has reinforced the effectiveness of the various vaccines, boosters, and prior infection in protecting against infection, hospitalization and death.

A recent study broke down hospitalizations associated with COVID-19 in adults between January 2021 and April of this year, based upon vaccination status.

The CDC is urging all eligible persons to receive a flu shot, but a new survey shows fewer adults are planning to get the vaccine this season.

Largest extended study of outcomes after rare myocarditis from mRNA COVID-19 vaccines finds most recover and regain quality of life.

“Vaccines are the most highly scrutinized public health interventions we know,” said Donald Alcendor, PhD.

The investigational therapy demonstrated time to first resolution of the five COVID-19 symptoms was significantly reduced in those treated with low dose of medication.

Interim data show a bivalent vaccine that contains the Omicron variant may be more effective.

These vaccines target the wild strain as well as the Omicron BA.4/BA.5 variants.

Investigators examined all-cause excess mortality and sought to uncouple it from COVID-19 in US states with high vaccination rates.

Bifidobacterium and Bacteroides in the gut microbiome are important to vaccine responsiveness and could be used in vaccine adjuvants in the future, a recent review shows.

The vaccine is available in adults 18 years and older.

Investigators surmise a natural bat exposure within certain areas of the world may correspond with lower COVID-19 incidence rates.

Injected COVID-19 mRNA vaccines alone were ineffective at producing mucosal antibody responses, according to a recent study that suggested seeking new strategies such as intranasal vaccines.